Simple Summary There is conflicting evidence on the impact of TP53 co-mutations on
survival in patients with EGFR-mutated advanced non-small cell lung cancer (aNSCLC) …

Introduction TP53 mutations are common in non-small cell lung cancer (NSCLC) and have
been reported as prognostic of poor outcome. The impact of TP53 co-mutations in epidermal …

Purpose TP53 mutation (MT) in epidermal growth factor receptor (EGFR)-MT non–small cell
lung cancer (NSCLC) is associated with poor response to targeted therapy; however, its …

Purpose To assess the prognostic impact of TP53 mutations in EGFR-mutant advanced
NSCLC patients treated with TKIs. Methods Studies exploring the clinical outcomes of EGFR …

Background The prognostic value of TP53 commutation in epidermal growth factor receptor
(EGFR) mutant lung cancer is controversial and we therefore conducted this systematic …

Background The prognostic significance of TP53 concurrent mutations in patients with
epidermal growth factor receptor (EGFR)-or anaplastic lymphoma kinase (ALK)-mutated …

Lung cancer is the leading cause of cancer-related deaths worldwide. As the most prevalent
molecular mutation subtypes in non-small cell lung cancer (NSCLC), EGFR-TKIs are …

Background How concurrent TP53 mutations affect targeted therapy of advanced Epidermal
Growth Factor Receptor (EGFR) mutant lung adenocarcinoma remains controversial …

Non-small cell lung cancer (NSCLC) is the most common cause of cancer death worldwide.
In non-squamous NSCLC, the identification of oncogenic drivers and the development of …

Background Mutations in TP53 are commonly found in patients with epidermal growth factor
receptor (EGFR) mutant advanced non–small-cell lung cancer (NSCLC). In this study, we …